Patents by Inventor Mahmoud A. Elsohly

Mahmoud A. Elsohly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220175937
    Abstract: New compositions are provided containing artemisinin dimers with high activity as anti-protozoal agents, including anti-malarial and anti-leishmanial properties, and methods for the treatment of protozoal infections, including malaria or leishmaniasis.
    Type: Application
    Filed: February 25, 2020
    Publication date: June 9, 2022
    Inventors: Mahmoud A. ElSohly, Waseem Gul
  • Patent number: 11344525
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: May 31, 2022
    Assignee: University of Mississippi
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Patent number: 11337950
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: May 24, 2022
    Assignee: University of Mississippi
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Patent number: 11337952
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: May 24, 2022
    Assignee: University of Mississippi
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Patent number: 11337951
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: May 24, 2022
    Assignee: University of Mississippi
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Patent number: 11117852
    Abstract: ?9-Tetrahydrocannabinol (?9-THC or THC) and cannabidiol (CBD) are major constituents of the Cannabis plant that have pharmacological properties with potential therapeutic value. This invention is directed to processes for large scale isolation of these two and other cannabinoids from the Cannabis sativa plant. This is accomplished through the discovery that protected amino acid esters of the cannabinoids are easier to separate using normal phase silica column chromatography. Mild base hydrolysis of the esters regenerates the free cannabinoids in a purified form. The invention is also applicable to the isolation of other cannabinoids from Cannabis extracts.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: September 14, 2021
    Assignee: UNIVERSITY OF MISSISSIPPI
    Inventors: Mahmoud A. ElSohly, Waseem Gul, Mohamed M. Radwan, Amira Samir Wanas
  • Publication number: 20210030708
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Application
    Filed: June 9, 2020
    Publication date: February 4, 2021
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Publication number: 20200383944
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Application
    Filed: June 9, 2020
    Publication date: December 10, 2020
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Publication number: 20200306217
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Application
    Filed: June 9, 2020
    Publication date: October 1, 2020
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Publication number: 20200297687
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Application
    Filed: June 9, 2020
    Publication date: September 24, 2020
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Publication number: 20200297688
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Application
    Filed: June 9, 2020
    Publication date: September 24, 2020
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Patent number: 10709681
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: July 14, 2020
    Assignee: UNIVERSITY OF MISSISSIPPI
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Publication number: 20200039908
    Abstract: ?9-Tetrahydrocannabinol (?9-THC or THC) and cannabidiol (CBD) are major constituents of the Cannabis plant that have pharmacological properties with potential therapeutic value. This invention is directed to processes for large scale isolation of these two and other cannabinoids from the Cannabis sativa plant. This is accomplished through the discovery that protected amino acid esters of the cannabinoids are easier to separate using normal phase silica column chromatography. Mild base hydrolysis of the esters regenerates the free cannabinoids in a purified form. The invention is also applicable to the isolation of other cannabinoids from Cannabis extracts.
    Type: Application
    Filed: April 4, 2018
    Publication date: February 6, 2020
    Inventors: Mahmoud A. ElSohly, Waseem Gul, Mohamed M. Radwan, Amira Samir Wanas
  • Publication number: 20190241498
    Abstract: A resveratrol ester has the following structure: R1, R2 and R3 are H or Each R4 is independently a carbon chain of 2 to 4 carbon atoms comprising a terminal carboxylic acid moiety, a carbon chain of 1 to 5 carbon atoms comprising an amine moiety, or R5 is a carbon chain of 3 or 4 carbon atoms having a terminal carboxylic acid moiety. At least one of R1, R2 and R3 is Salts of resveratrol esters are also included.
    Type: Application
    Filed: September 7, 2018
    Publication date: August 8, 2019
    Inventors: Mahmoud A. ElSohly, Waseem Gul, Jeptha N. Cole
  • Patent number: 10322103
    Abstract: The present invention, in one or more embodiments, comprises derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecyl catechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising urushiol esters of general formula (IA) [Formula should be entered here] tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a formulation containing at least one urushiol ester compound.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: June 18, 2019
    Assignee: UNIVERSITY OF MISSISSIPPI
    Inventors: Mahmoud Elsohly, Waseem Gul, Mohammad Khalid Ashfaq
  • Publication number: 20190031601
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Application
    Filed: January 27, 2017
    Publication date: January 31, 2019
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Wasseem Gul, Mohammad Khalid, Kenneth Joseph Sufka, Hannah Marie Harris
  • Patent number: 10099995
    Abstract: A resveratrol ester has the following structure: R1, R2 and R3 are H or Each R4 is independently a carbon chain of 2 to 4 carbon atoms comprising a terminal carboxylic acid moiety, a carbon chain of 1 to 5 carbon atoms comprising an amine moiety, or R5 is a carbon chain of 3 or 4 carbon atoms having a terminal carboxylic acid moiety. At least one of R1, R2 and R3 is Salts of resveratrol esters are also included.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: October 16, 2018
    Assignee: Cole Research and Design, LLC
    Inventors: Mahmoud A. ElSohly, Waseem Gul, Jeptha N. Cole
  • Publication number: 20180078520
    Abstract: The present invention, in one or more embodiments, comprises derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecyl catechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising urushiol esters of general formula (IA) [Formula should be entered here] tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a formulation containing at least one urushiol ester compound.
    Type: Application
    Filed: January 12, 2016
    Publication date: March 22, 2018
    Inventors: Mahmoud ELSOHLY, Waseem GUL, Mohammad Khalid
  • Publication number: 20170183290
    Abstract: A resveratrol ester has the following structure: R1, R2 and R3 are H or Each R4 is independently a carbon chain of 2 to 4 carbon atoms comprising a terminal carboxylic acid moiety, a carbon chain of 1 to 5 carbon atoms comprising an amine moiety, or R5 is a carbon chain of 3 or 4 carbon atoms having a terminal carboxylic acid moiety. At least one of R1, R2 and R3 is Salts of resveratrol esters are also included.
    Type: Application
    Filed: December 23, 2016
    Publication date: June 29, 2017
    Inventors: Mahmoud A. ElSohly, Waseem Gul, Jeptha N. Cole
  • Patent number: 9630941
    Abstract: Suppository, hot melt and ophthalmic formulations containing amino esters of the formulae (I), (II) and (III), where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: April 25, 2017
    Assignee: The University of Mississippi
    Inventors: Mahmoud A. Elsohly, Waseem Gul, Michael A. Repka, Soumyajit Majumdar, Mohammad Khalid Ashfaq